Czynniki patogeniczności Staphylococcus Pettenkoferi w ranach stóp i zapaleniu kości u pacjentów z cukrzycą (PETTENK-OS)
Ocena czynników patogeniczności Staphylococcus Pettenkoferi w ranach stóp i zapaleniu kości u pacjentów z cukrzycą. Badanie PETTENK-OS
Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
- Inny: Molecular epidemiology of the collection
- Inny: Study of the resistome of the S. pettenkoferi population
- Inny: Study of the virulome of the S. pettenkoferi population
- Inny: Study of the resistance profiles of all S. pettenkoferi isolates
- Inny: Selection of strains for in-depth phenotypic study
- Inny: Selection of strains (n=3) for the virulence study
Szczegółowy opis
Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.
At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.
Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.
A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.
Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Gard
-
Nîmes, Gard, Francja, 30029
- Nîmes University Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.
Opis
Inclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Exclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: OTHER
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Ramy czasowe: Day 0 to 3 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms). |
Day 0 to 3 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Ramy czasowe: 3 - 6 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin:osteitis
Ramy czasowe: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: non-diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: blood cultures
Ramy czasowe: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: nasal carriage
Ramy czasowe: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: osteitis
Ramy czasowe: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: non-diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: blood cultures
Ramy czasowe: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: nasal carriage
Ramy czasowe: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: osteitis
Ramy czasowe: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: diabetic wounds
Ramy czasowe: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: blood cultures
Ramy czasowe: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: nasal carriage
Ramy czasowe: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Phenotypic resistance profiles in the population in a subsample of 85 strains
Ramy czasowe: 6 - 14 months
|
The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Ramy czasowe: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Ramy czasowe: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Ramy czasowe: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Ramy czasowe: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Ramy czasowe: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Ramy czasowe: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Ramy czasowe: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Ramy czasowe: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Ramy czasowe: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Ramy czasowe: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Ramy czasowe: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Ramy czasowe: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Ramy czasowe: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Ramy czasowe: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Ramy czasowe: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Ramy czasowe: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Ramy czasowe: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Ramy czasowe: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Ramy czasowe: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Ramy czasowe: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Ramy czasowe: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Ramy czasowe: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Ramy czasowe: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Ramy czasowe: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Ramy czasowe: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Ramy czasowe: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Ramy czasowe: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Ramy czasowe: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Chloé MAGNAN, Dr., Nîmes University Hospital, FRANCE
Publikacje i pomocne linki
Publikacje ogólne
- Magnan C, Curtil-Dit-Galin M, Morsli M, Cattoir V, Piau-Couapel C, Soderquist B, Kahl BC, Denis O, Rwayane K, Corvec S, Francois P, Salipante F, Pantel A, Dunyach-Remy C, Laurent F, Lavigne JP; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Staphylococcus pettenkoferi: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. Emerg Microbes Infect. 2026 Dec;15(1):2724635. doi: 10.1080/22221751.2026.2724635. Epub 2026 Sep 16.
- Magnan C, Plumet L, Morsli M, Dunyach-Remy C, Pouget C, Sotto A, Molle V, Lavigne J-P. A narrative review of coagulase-negative staphylococci in diabetic foot infections. Clin Microbiol Rev. 2025 Dec 11;38(4):e0012125. doi: 10.1128/cmr.00121-25. Epub 2025 Nov 4.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Choroby kości
- Choroby układu mięśniowo-szkieletowego
- Choroby naczyniowe
- Choroby układu krążenia
- Choroby metaboliczne
- Zaburzenia metabolizmu glukozy
- Angiopatie cukrzycowe
- Powikłania cukrzycy
- Choroby skórne
- Owrzodzenie skóry
- Owrzodzenie nogi
- Neuropatie cukrzycowe
- Owrzodzenie stopy
- Choroby żywieniowe i metaboliczne
- Choroby skóry i tkanki łącznej
- Cukrzyca
- Infekcje
- Stopa cukrzycowa
- Zapalenie kości
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NIMAO/2023-2/CM-01
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .